Shenzhen adheres to the differentiated development policy and focuses on promoting the high-quality development of the cell and gene therapy industry. Through the formulation of laws and regulations, the creation of scientific research and innovation platform, and the ability to gather talents, a good industrial innovation environment and a complete legal system guarantee will be formed to escort the cell and gene therapy industry.
(1) Shenzhen Cell Valley won the major project certificate of Shenzhen Development and Reform Commission in 2022;
（2）The one-stop cell and gene therapy CRO/CDMO service platform - South China Cell Factory project was selected as the only major public service platform for the biomedical industry in Shenzhen;
(3) On July 8, 2022, the groundbreaking ceremony of the Shenzhen Cell Valley-South China Cell Factory Project was officially held in Hepuray Biomedical Ecological Park, Pingshan District, Shenzhen.
Leaders attending the ceremony included the deputy director of the Standing Committee of the Shenzhen Municipal People's Congress of Guangdong Province, the chairman of the Municipal Association of Science and Technology, the vice-chairman of the Guangdong Provincial Committee of the Jiu San Society and the chairman of the Shenzhen Municipal Committee, Jiang Yuyang, the chairman of the Shenzhen Municipal Committee of the Jiu San Society, and the director of the Shenzhen Pingshan District People's Congress Standing Committee, Liao Shuhua, and other governmental representatives; academician of the Chinese Academy of Sciences, Acting Vice-President of Southern University of Science and Technology (SUSTech), and professor of the Medical School Chair, Dongfeng Gu; chief scientist of Xingwan Bio, foreign member of the Russian Academy of Engineering Zhang Dan, President of Pingshan Biomedical Transformation Research Institute of SUSTech and Foreign Academician of Russian Academy of Engineering Zhang Xumu, Vice President of Shenzhen Institute of Pharmaceutical Inspection and Research Wang Xiaowei and other academic representatives, Lan Lan, Chairman of Pingshan Industrial Capital Investment Co. Ltd. and Shi Yuanyuan, founder of Shenzhen Cell Valley Biomedical Company.
(4) The subsidia
ry Junhou won the ninth batch of innovative scientific research team projects in Zhongshan City;
(5) Close strategic cooperation with the Shenzhen Institute for Drug Control and Research, the Dawan Branch Center for Drug Review and Inspection of the State Drug Administration, the Shenzhen Hospital of Peking University and other industry-university-research institutions and relevant government departments, leading and participating in the formulation of industry standards for cell and gene therapy, and bearing the burden of formulating industry standards from research and development, audit, production, transportation, clinical, medical and other aspects, Better promote the standardization and industrialization of cell and gene therapy products.
(6) The subsidiary Junhou Biotech has won the title of "Top 50 Innovative Biotechnology Enterprises in Guangdong, Hong Kong and Macao Bay Area" for three times;
(7) The subsidiary Junhou Biology won the ninth batch of innovative scientific research team projects and support funds in 2022, rent and decoration of Zhongshan City, and subsidy for the establishment of doctor station.
Government Support
Official WeChat Account 
